Warfarin metabolism and drug-drug interactions.
O'Reilly
R A
RA
Department of Medicine, Santa Clara Valley Medical Center, Stanford University School of Medicine, California.
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics; D001241:Aspirin / Q000493:pharmacokinetics; D001463:Barbiturates / Q000493:pharmacokinetics; D002792:Cholestyramine Resin / Q000008:administration & dosage; D002994:Clofibrate / Q000494:pharmacology; D004232:Diuretics / Q000493:pharmacokinetics; D004347:Drug Interactions; D000431:Ethanol / Q000493:pharmacokinetics; D006801:Humans; D012293:Rifampin / Q000493:pharmacokinetics; D014812:Vitamin K / Q000378:metabolism; D014859:Warfarin / Q000378:metabolism* / Q000493:pharmacokinetics
D000900:Anti-Bacterial Agents; D001463:Barbiturates; D004232:Diuretics; D002792:Cholestyramine Resin; D014812:Vitamin K; D000431:Ethanol; D014859:Warfarin; D002994:Clofibrate; D001241:Aspirin; D012293:Rifampin